Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.
Aranow C, Allaart CF, Amoura Z, Bruce IN, Cagnoli PC, Chatham WW, Clark KL, Furie R, Groark J, Urowitz MB, van Vollenhoven R, Daniels M, Fox NL, Gregan YI, Henderson RB, van Maurik A, Ocran-Appiah JC, Oldham M, Roth DA, Shanahan D, Tak PP, Teng YO. Aranow C, et al. Ann Rheum Dis. 2024 Oct 21;83(11):1502-1512. doi: 10.1136/ard-2024-225686. Ann Rheum Dis. 2024. PMID: 39159997 Free PMC article. Clinical Trial.
Antibody-mediated podocytopathies: a disease entity that implies immunotherapy.
Kronbichler A, Barnini C, Matyjek A, Gauckler P, Bruchfeld A, Caravaca-Fontan F, Floege J, Frangou E, Mirioglu S, Moran SM, Stevens KI, Teng YKO, Steiger S. Kronbichler A, et al. Among authors: teng yko. Nephrol Dial Transplant. 2024 Jul 17:gfae166. doi: 10.1093/ndt/gfae166. Online ahead of print. Nephrol Dial Transplant. 2024. PMID: 39020250 No abstract available.
Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy.
van Schaik M, de Vries APJ, Bemelman FJ, Rabelink TJ, Trouw LA, van Kooten C, Teng YKO. van Schaik M, et al. Among authors: teng yko. Kidney Int Rep. 2024 Feb 24;9(6):1919-1922. doi: 10.1016/j.ekir.2024.02.1402. eCollection 2024 Jun. Kidney Int Rep. 2024. PMID: 38899188 Free PMC article. No abstract available.
Immunoengineering for autoimmune-kidney disease.
Mirioglu S, Bruchfeld A, Caravaca-Fontan F, Fernandez-Juarez GM, Floege J, Frangou E, Goumenos D, Griffith M, Moran SM, Stevens KI, Teng YKO, Turkmen K, Kronbichler A, Steiger S. Mirioglu S, et al. Among authors: teng yko. Nephrol Dial Transplant. 2024 Nov 27;39(12):1934-1937. doi: 10.1093/ndt/gfae140. Nephrol Dial Transplant. 2024. PMID: 38889934 No abstract available.
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
Arends EJ, Zlei M, Tipton CM, Cotic J, Osmani Z, de Bie FJ, Kamerling SWA, van Maurik A, Dimelow R, Gregan YI, Fox NL, Rabelink TJ, Roth DA, Sanz I, van Dongen JJM, van Kooten C, Teng YKO. Arends EJ, et al. Among authors: teng yko. Rheumatology (Oxford). 2024 Sep 1;63(9):2387-2398. doi: 10.1093/rheumatology/keae286. Rheumatology (Oxford). 2024. PMID: 38775637 Free PMC article.
116 results